Overview Tumor mutational burden (TMB) is a measurement of the number of mutations carried by a tumor cell genome. By comparing DNA sequences from a patient’s healthy tissue and tumor cells, and using a number of complex algorithms, scientists can determine the number of acquired somatic mutations present in tumors but not in normal tissues.1 NGS is the primary method employed to measure TMB, either through targeted panels or whole exome sequencing (WES);2 the latter is considered the gold-standard measurement today.
Advancing Immuno-Oncology Biomarker Validation with Industry’s First NGS-based TMB Reference Materials
Category: NGS, Immuno-Oncology
0 Comments Click here to read/write comments